Management of BRAF-mutant metastatic colorectal cancer

被引：2
|
作者：
Burge, Matthew [1 ,2 ]
Whitehall, Vicki [2 ,3 ,4 ]
机构：
[1] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
[2] Univ Queensland, Brisbane, Qld, Australia
[3] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia
[4] Pathol Queensland, Brisbane, Qld, Australia
来源：
COLORECTAL CANCER | 2016年 / 5卷 / 04期
关键词：
BRAF; colorectal cancer; metastasis; therapy;
D O I：
10.2217/crc-2016-0012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：131 / 133
页数：3
相关论文
共 50 条
  • [41] VemurafenibResistance to vemurafenib in BRAF-mutant metastatic melanoma: case report
    Reactions Weekly, 2015, 1533 (1) : 437 - 437
  • [42] Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
    Ikoma, Tatsuki
    Shimokawa, Mototsugu
    Kotaka, Masahito
    Matsumoto, Toshihiko
    Nagai, Hiroki
    Boku, Shogen
    Shibata, Nobuhiro
    Yasui, Hisateru
    Satake, Hironaga
    BMC CANCER, 2021, 21 (01)
  • [43] Axillary Lymph Node Involvement, a Unique Pattern of Metastasis in BRAF-Mutant Colorectal Cancer
    Lipsyc, Marla D.
    Yaeger, Rona
    Dengel, Lynn T.
    Saltz, Leonard
    JAMA ONCOLOGY, 2015, 1 (05) : 686 - 687
  • [44] Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
    Kopetz, Scott
    Yoshino, Takayuki
    Van Cutsem, Eric
    Eng, Cathy
    Kim, Tae Won
    Wasan, Harpreet Singh
    Desai, Jayesh
    Ciardiello, Fortunato
    Yaeger, Rona
    Maughan, Timothy S.
    Beyzarov, Elena
    Zhang, Xiaoxi
    Ferrier, Graham
    Zhang, Xiaosong
    Tabernero, Josep
    NATURE MEDICINE, 2025, : 901 - 908
  • [45] Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
    Oddo, Daniele
    Sennott, Erin M.
    Barault, Ludovic
    Valtorta, Emanuele
    Arena, Sabrina
    Cassingena, Andrea
    Filiciotto, Genny
    Marzolla, Giulia
    Elez, Elena
    van Geel, Robin M. J. M.
    Bartolini, Alice
    Crisafulli, Giovanni
    Boscaro, Valentina
    Godfrey, Jason T.
    Buscarino, Michela
    Cancelliere, Carlotta
    Linnebacher, Michael
    Corti, Giorgio
    Truini, Mauro
    Siravegna, Giulia
    Grasselli, Julieta
    Gallicchio, Margherita
    Bernards, Rene
    Schellens, Jan H. M.
    Tabernero, Josep
    Engelman, Jeffrey A.
    Sartore-Bianchi, Andrea
    Bardelli, Alberto
    Siena, Salvatore
    Corcoran, Ryan B.
    Di Nicolantonio, Federica
    CANCER RESEARCH, 2016, 76 (15) : 4504 - 4515
  • [46] Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
    Tatsuki Ikoma
    Mototsugu Shimokawa
    Masahito Kotaka
    Toshihiko Matsumoto
    Hiroki Nagai
    Shogen Boku
    Nobuhiro Shibata
    Hisateru Yasui
    Hironaga Satake
    BMC Cancer, 21
  • [47] Not All BRAF-Mutant Metastatic Colorectal Cancers Are Identical: Distinct Clinical Consequences of non-V600BRAF Mutations
    Van Cutsem, Eric
    Dekervel, Jeroen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) : 2598 - +
  • [48] Inhibition of BRAF and MEK in BRAF-mutant melanoma
    Smalley, Keiran S. M.
    Sondak, Vernon K.
    LANCET, 2015, 386 (9992): : 410 - 412
  • [49] Vemurafenib: the first drug approved for BRAF-mutant cancer
    Bollag, Gideon
    Tsai, James
    Zhang, Jiazhong
    Zhang, Chao
    Ibrahim, Prabha
    Nolop, Keith
    Hirth, Peter
    NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (11) : 873 - 886
  • [50] Vemurafenib: the first drug approved for BRAF-mutant cancer
    Gideon Bollag
    James Tsai
    Jiazhong Zhang
    Chao Zhang
    Prabha Ibrahim
    Keith Nolop
    Peter Hirth
    Nature Reviews Drug Discovery, 2012, 11 : 873 - 886
12345